High-dose aflibercept

DRUG2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Diabetic Macular EdemaNeovascular (Wet) Age-Related Macular DegenerationType 1 Diabetes MellitusType 2 Diabetes Mellitus

Phase 2

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration

CompletedNCT04126317

Regeneron PharmaceuticalsNeovascular (Wet) Age-Related Macular Degeneration

Start: 2019-11-04End: 2021-11-30Updated: 2023-08-14

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

CompletedNCT04429503

Regeneron PharmaceuticalsDiabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus

Start: 2020-06-29End: 2024-06-18Updated: 2025-08-08

Related Papers

Intraocular Pressure Outcomes with Intravitreal Aflibercept 8 mg: A 96-Week Pooled Analysis from PULSAR and PHOTON

Ophthalmology and Therapy2026-06-13

A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema

Ophthalmic Research2026-05-15

Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial.

2025-12-26

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial.

2025-11-10

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.

2024-03-0761 citations

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration

JAMA Ophthalmology2023-08-0387 citations